Home / Clinical Laboratory / Clinical Analyzer Calibrators and Reagents / Reagents / Reagent Kit / Reagent Kit Atellica® IM Cancer CA 15‑3® For Atellica® IM Analyzer 100 Tests10995485
Picture of Reagent Kit Atellica® IM Cancer CA 15‑3® For Atellica® IM Analyzer 100 Tests10995485

Reagent Kit Atellica® IM Cancer CA 15‑3® For Atellica® IM Analyzer 100 Tests10995485

Reagent-Kit-Atellica®-IM-Cancer-CA-15‑3®-For-Atellica®-IM-Analyzer-100-Tests10995485

SKU #

#1109032

MPN #

10995485

Brand

Siemens

Stock

In Stock

Quantity

100

Features

REAGENT, IMMUNOASSAY ATELLICA CA 15-3 (100TESTS) D/S

$801.01 USD

Attribute Name Attribute Value
McKesson # 1109032
Manufacturer # 10995485
Brand Atellica® IM
Manufacturer Siemens
Application Reagent Kit
For Use With For Atellica® IM Analyzer
Form Liquid
Number of Tests 100 Tests
Product Dating McKesson Acceptable Dating: we will ship >= 90 days
Sample Type Serum Sample
Storage Requirements Requires Refrigeration
Test Name CA 15‑3®
Test Type Cancer
Type Chemiluminescent Immunoassay
UNSPSC Code 41116004

Similar Items

Underarm Crutches McKesson Aluminum Frame Tall Adult 350 lbs. Weight Capacity Push Button - Adjustment

One Size Fits Most White NonSterile Not Rated 8211

In Stock

PR/1 $9.76 USD

Underarm Crutches McKesson Aluminum Frame Tall Adult 350 lbs. Weight Capacity Push Button - Adjustment

One Size Fits Most White NonSterile Not Rated 8211

In Stock

PR/1 $9.76 USD

Underarm Crutches McKesson Aluminum Frame Tall Adult 350 lbs. Weight Capacity Push Button - Adjustment

One Size Fits Most White NonSterile Not Rated 8211

In Stock

PR/1 $9.76 USD

Underarm Crutches McKesson Aluminum Frame Tall Adult 350 lbs. Weight Capacity Push Button - Adjustment

One Size Fits Most White NonSterile Not Rated 8211

In Stock

PR/1 $9.76 USD

  • The Atellica® IM CA 15‑3® (CA 15‑3) assay is for in vitro diagnostic use in the quantitative serial determination of cancer antigen CA 15‑3 in human serum using the Atellica® IM Analyzer
  • Atellica IM CA 15‑3 assay is useful for monitoring the course of disease and therapy in metastatic breast cancer patients, and for detection of recurrence in previously treated Stage II, with greater than two positive lymph nodes, or Stage III breast cancer patients